Skip to main content

Pylarify FDA Approval History

Last updated by Judith Stewart, BPharm on June 2, 2021.

FDA Approved: Yes (First approved May 26, 2021)
Brand name: Pylarify
Generic name: piflufolastat F 18
Dosage form: Injection
Company: Progenics Pharmaceuticals, Inc.
Treatment for: Positron Emission Tomography Imaging

Pylarify (piflufolastat F 18) is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.

Development timeline for Pylarify

May 27, 2021Approval FDA Approves Pylarify¬†(piflufolastat F 18) PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.